West Pharmaceutical Services Inc.
WST evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for WST—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WST
West Pharmaceutical Services Inc. (WST) is a global manufacturer of integrated containment and delivery systems for injectable drugs, serving the pharmaceutical and biotech industries with proprietary packaging, high-value components, and contract manufacturing services.
Key risk: Currency exchange fluctuations
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 13 clinical trials · 8 catalysts for West Pharmaceutical Services Inc..
West Pharmaceutical Services Inc. (WST) is a global manufacturer of integrated containment and delivery systems for injectable drugs, serving the pharmaceutical and biotech industries with proprietary packaging, high-value components, and contract manufacturing services.
- Full-year 2025 net sales of $3.1 billion, a 6.3% increase; organic net sales increase of 4.3% [sec · filed 2026-03-12].
- Full-year 2025 reported-diluted EPS of $6.79, adjusted-diluted EPS of $7.29 [sec · filed 2026-03-12].
- Operating cash flow of $755 million in 2025 [sec · filed 2026-03-12].
- As of 2026-06-30, cash & equivalents $435.8M, total revenue $872.3M, net income $154.0M, shareholders' equity $3,176.0M, total debt $202.9M [latest reported financials].
- Contract Manufacturing segment represented 19% of 2025 net sales, with Dublin facility ramping production for obesity and diabetes delivery devices [sec · filed 2026-03-12].
What works
- Market leadership in injectable solutions with a strong position in high-value components (HVP) and delivery devices, supported by favorable biotech industry trends [sec · filed 2026-03-12] [sec · filed 2025-03-21].
- Consistent dividend growth, having increased the dividend for the 32nd consecutive year [sec · filed 2025-03-21].
- Ongoing investment in global operations, including capacity expansion for HVP components and GLP-1 market support, and innovative manufacturing practices [sec · filed 2025-03-21].
- Strong customer relationships built on scientific expertise and regulatory insight, with high participation in providing primary containment for approved new molecular entities [sec · filed 2025-03-21].
What to weigh
- Full-year 2024 net sales declined 1.9% and adjusted-diluted EPS declined 16.5%, indicating recent volatility [sec · filed 2025-03-21].
- Exposure to currency fluctuations, particularly the Euro, SGD, Danish Krone, Yen, and other currencies, which can impact results [sec_mda · as of 2026-07-23].
- Competition from other providers, including customers' in-house operations and lower-cost producers in emerging markets, could affect unit volume, price, and profitability [sec_mda · as of 2026-04-23].
- Dependence on customer inventory requirements and manufacturing plans, which can alter demand unpredictably [sec_mda · as of 2026-04-23].
From the filings
Quoted directly from source documents.
2025 net sales of $3.1 billion, 6.3% increase
“Full-year 2025 net sales of$3.1 billion, a 6.3% increase;organic net sales* increase of 4.3%; currency translationincreased net sales by 200 basis points”
SEC filings · March 12, 2026
2025 adjusted-diluted EPS of $7.29, 8.0% increase
“Full-year 2025 reported-diluted EPS of$6.79, an increase of1.5%, and full-year 2025 adjusted-diluted EPS* of $7.29increased 8.0%”
SEC filings · March 12, 2026
Operating cash flow of $755 million in 2025
“We delivered operating cash flow of $755 million a”
SEC filings · March 12, 2026
Contract Manufacturing segment 19% of 2025 net sales
“Our Contract Manufacturing segment, which represents 19% of our 2025 net sales, delivered growth and operational improvements”
SEC filings · March 12, 2026
Catalyst timeline
- 2026-10-01 · Phase 1 Start: Intelligent Diagnosis and Effective Prescription Verification of Sleep Disorders Complicated With Ob — Initiation of a Phase 1 study for a sleep disorder indication; early-stage clinical milestone.
- 2026-12-01 · Phase 3 Topline: A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis — Topline data readout for ZILRETTA in glenohumeral osteoarthritis; key efficacy and safety results.
- 2027-01-10 · Phase 3 Topline: A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP3 — Topline data readout for AP3; multi-regional Phase 3 study results.
- 2027-12-01 · Phase 3 Topline: A Multi-centered, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safet — Topline data readout for a placebo-controlled Phase 3 study; efficacy and safety evaluation.
Risks & what to watch (3)›
Key risks
- Currency exchange fluctuations — Relative strength of USD vs. Euro, SGD, DKK, Yen, and other currencies can affect financial results [sec_mda · as of 2026-07-23].
- Competitive pressure — Competition from in-house operations and lower-cost producers may impact unit volume, price, and profitability [sec_mda · as of 2026-04-23].
- Customer demand variability — Changes in customer inventory requirements and manufacturing plans can alter demand unpredictably [sec_mda · as of 2026-04-23].
What to watch
- Commercial drug-handling operations at Dublin facility expected to commence in 2026 [sec · filed 2026-03-12].
- Continued ramp of production for obesity and diabetes delivery devices at Dublin facility [sec · filed 2026-03-12].
- Progress on capacity expansion for HVP components and GLP-1 market support [sec · filed 2025-03-21].
- Impact of currency translation on future net sales and earnings [sec_mda · as of 2026-07-23].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 30, 2026 · How we verify sources →
Run West Pharmaceutical Services Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available West Pharmaceutical Services Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.36 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
8 upcoming, next in ~32d
0 buys · 2 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
751
Total value held
$17.41B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 9,366,572 | $2.35B |
| blackrock, inc. | 6,836,714 | $1.71B |
| vanguard portfolio management llc | 4,094,009 | $1.03B |
| state street corp | 3,293,778 | $825.6M |
| bank of new york mellon corp | 2,465,858 | $618.0M |
| generation investment management llp | 2,243,976 | $562.4M |
| geode capital management, llc | 1,912,455 | $477.5M |
| morgan stanley | 1,458,282 | $365.5M |
| brown advisory inc | 1,340,877 | $336.1M |
| longview partners (guernsey) ltd | 1,315,403 | $329.7M |
Showing top 10 of 751 institutional holders of West Pharmaceutical Services Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 10, 2026- % of float
- 4.4%
- Days to cover
- 3.2
- Shares short
- 2,662,538
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WST short interestGovernance
Frequently asked questions
What is the AI investment thesis for West Pharmaceutical Services Inc.?
West Pharmaceutical Services Inc. (WST) is a global manufacturer of integrated containment and delivery systems for injectable drugs, serving the pharmaceutical and biotech industries with proprietary packaging, high-value components, and contract manufacturing services.
What is West Pharmaceutical Services Inc.'s next catalyst?
West Pharmaceutical Services Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: Intelligent Diagnosis and Effective Prescription Verification of Sleep Disorders Complicated With Ob" — expected October 1, 2026.
Who is the CEO of West Pharmaceutical Services Inc.?
Mr. Eric Mark Green is the chief executive officer of West Pharmaceutical Services Inc. (WST).
Where is West Pharmaceutical Services Inc. headquartered?
West Pharmaceutical Services Inc. (WST) is headquartered in Exton, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.